The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Introduction: The preclinical phase of Alzheimer's disease (AD) is optimal for identifying early pathophysiological events and developing prevention programs, which are shared aims of the ALFA project, including the ALFA registry and parent cohort and the nested ALFA+ cohort study. Methods: The ALFA parent cohort baseline visit included full cognitive evaluation, lifestyle habits questionnaires, DNA extraction, and MRI. The nested ALFA+ study adds wet and imaging biomarkers for deeper phenotyping. Results: A total of 2743 participants aged 45 to 74 years were included in the ALFA parent cohort. We show that this cohort, mostly composed of cognitively normal offspring of AD patients, is enriched for AD genetic risk factors. Discussion: The ALFA project represents a valuable infrastructure that will leverage with different studies and trials to prevent AD. The longitudinal ALFA+ cohort will serve to untangle the natural history of the disease and to model the preclinical stages to develop successful trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815 · cited 1×
“The EQ-5D-3L scale [36,37] was used to obtain the participants’ perceived quality of life; physical activity was measured with the Spanish short version of the Minnesota Leisure Time Physical Activity Questionnaire [38]; dietary habits were gathered by a 166item food frequency questionnaire; alcohol, tobacco, and drug…”
MethodClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“In addition, disease-modifying pharmacological interventions on both mild moderate and late-stage AD persons have yet to produce significant clinical benefits [48].”
BackgroundDetecting anxiety and depression in general medical settings.
Goldberg, D., Bridges, K., Duncan-Jones, P., & Grayson, D. (1988) · BMJ · doi:10.1136/bmj.297.6653.897 · Cited by 1,210
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 1×
“studies show that AD pathology develops for several years or even decades before clinical symptoms appear; this silent asymptomatic period of the disease is referred to as the preclinical stage of AD [11].”
Background
Cited by
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638
Self-citationSuárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401
Self-citationGascon, M., Sánchez-Benavides, G., Dadvand, P., Martínez, D., Gramunt, N., Gotsens, X., Cirach, M., Vert, C., Molinuevo, J. L., Crous-Bou, M., et al. (2018) · Environmental Research · doi:10.1016/j.envres.2018.01.012 · Cited by 377
Self-citationMilà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01925-w · Cited by 353
Self-citationAPOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02931-w · Cited by 369
Self-citation
Metadata
- Authors
- Molinuevo, J. L., Gramunt, N., Gispert, J. D., Fauria, K., Esteller, M., Minguillon, C., Sánchez‐Benavides, G., Huesa, G., Morán, S., Dal‐Ré, R., & Camí, J.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2016-03-03
- Volume
- 2
- Issue
- 2
- Pages
- 82-92
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W2301075806
- Cited by
- 182
- References
- 19
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.trci.2016.02.003
- The paper
- Molinuevo, J. L., Gramunt, N., Gispert, J. D., Fauria, K., Esteller, M., Minguillon, C., Sánchez‐Benavides, G., Huesa, G., Morán, S., Dal‐Ré, R., & Camí, J. (2016). The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions. https://doi.org/10.1016/j.trci.2016.02.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.